siRNA-IkappaBalpha

siRNA-IkappaBalpha is a small interfering RNA (siRNA) designed to target and knock down the expression of IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha), encoded by the NFKBIA gene. IκBα is a key negative regulator of the canonical NF-κB transcription factor pathway. By silencing IκBα, the siRNA prevents the inhibition of NF-κB, thereby activating canonical NF-κB signaling. In the context of cancer immunotherapy, researchers at Vanderbilt University have formulated this siRNA into mannose-decorated polymeric nanoparticles (IκBα-MnNPs) to selectively target M2-like tumor-associated macrophages (TAMs) via the CD206 (mannose receptor). Repolarization of these immunosuppressive TAMs into a pro-inflammatory, anti-tumor M1 phenotype has demonstrated therapeutic efficacy in preclinical murine models of breast cancer metastasis (to lung and bone) and ovarian cancer, reducing tumor burden and remodeling the tumor microenvironment without apparent systemic toxicity.

Other names

IkappaBalpha siRNAIκBα siRNAIκBα-MnNPIκBα-MnNPssiRNA against IkappaBalphasiRNA-IκBα